🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 74 of 151

  1. La composición cualitativa y cuantitativa de cada sobre de placebo es la siguiente: Bicarbonato sódico 563,75 mg Diluyente/generador de efervescencia Ph Eur Ácido cítrico 410,0 mg Diluyente/generador de efervescencia Ph Eur Maltodextrina 651,25 mg Diluyente Ph Eur Sílice coloidal anhidra 10,0 mg Fluidificante/desecante interno Ph Eur Manitol 769,0 mg Diluyente Ph Eur Sacarina sódica 24,0 mg Edulcorante Ph Eur Aroma de naranja 72,0 mg Saborizante Espec.. interna Masa nominal 2.500 mg El polvo efervescente se

    The George Institute

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  2. Labetalol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  3. Lactezin

    United Therapeutics Europe Ltd

    Hormonal Acne

    phase 2 other active

    1 trial

  4. Lactulose

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Constipation

    phase 2 small molecule completed

    1 trial

  5. Lacutamab

    Lacuna Pharma Pty Ltd

    Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF).

    phase 2 small molecule active

    1 trial

  6. Ladarixin, Placebo to match Ladarixin

    Dompe' Farmaceutici S.p.A.

    Recent onset Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  7. Laminectomy

    Biotech Pharmaceutical Co.,

    Acute Spinal Cord Injury

    phase 2 other active

    1 trial

  8. Lamivudina Aurovitas 300 mg comprimidos recubiertos con película EFG

    MEDA Pharma GmbH & Co. KG

    Mild Cognitive impairment due to Alzheimer Disease

    phase 2 small molecule active

    1 trial

  9. Lamotrigine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  10. Lanraplenib

    Lakefront Biotherapeutics NV

    Sjogren's Syndrome

    phase 2 small molecule completed

    1 trial

  11. Lanraplenib

    Lakefront Biotherapeutics NV

    Cutaneous Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  12. Lansoprazole

    Takeda

    Esophagitis

    phase 2 small molecule completed

    1 trial

  13. Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  14. Lanthanum Polystyrene Sulphonate Powder

    The First People's Hospital of Lianyungang

    Hyperphosphatemia

    phase 2 small molecule active

    1 trial

  15. Lanthanum carbonate

    Takeda

    Chronic Kidney Disease

    phase 2 small molecule completed

    2 trials

  16. Lapaquistat acetate and fenofibrate

    Takeda

    Hyperlipidemias

    phase 2 small molecule completed

    1 trial

  17. Lapatinib

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  18. Laquinimod

    Teva Pharma GmbH

    Lupus Nephritis

    phase 2 small molecule completed

    1 trial

  19. Laquinimod

    Teva Pharma GmbH

    Lupus Arthritis

    phase 2 small molecule completed

    1 trial

  20. Laquinimod

    Teva Pharma GmbH

    Huntington's Disease

    phase 2 small molecule completed

    1 trial

  21. Laquinimod

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  22. Laquinimod 0.6

    Teva Pharma GmbH

    Relapsing Multiple Sclerosis

    phase 2 small molecule terminated

    1 trial

  23. Larazotide Acetate

    Teva Pharma GmbH

    Celiac Disease

    phase 2 small molecule completed

    1 trial

  24. Larotrectinib Bayer, Larotrectinib Bayer, Larotrectinib Bayer

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

  25. Larotrectinib Bayer, Larotrectinib Bayer, Larotrectinib Bayer

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

  26. Lasofoxifene

    LIGAND PHARMACEUTICALS INC

    Bone Loss

    phase 2 small molecule completed

    1 trial

  27. Late immunity following single immunization with GA2 sporozoites (GACHA)

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  28. Leflunomide

    Sanofi Pasteur

    Systemic Lupus Eythematosus (SLE)

    phase 2 small molecule completed

    1 trial

  29. Leflunomide CF 20 mg, filmomhulde tabletten, Hydorxychloroquine 200mg/Placebo, Hydroxychloroquinesulfaat 200 mg Focus, filmomhulde tabletten, Hydroxychloroquinesulfaat CF 200 mg, filmomhulde tabletten, Leflunomide Mylan 10 mg, filmomhulde tabletten, Leflunomide 20mg/Placebo, Leflunomide Mylan 20 mg, filmomhulde tabletten, Plaquenil 200 mg, filmomhulde tabletten

    Disc Medicine

    primary Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  30. Lemborexant

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Interaction

    phase 2 small molecule completed

    1 trial

  31. Lenabasum 20 mg

    Corbus Pharmaceuticals Holdings

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  32. Lenalidomide

    United Therapeutics Europe Ltd

    Recurrent Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  33. Lenalidomide

    The First People's Hospital of Lianyungang

    PTCL, NOS

    phase 2 small molecule active

    1 trial

  34. Lenalidomide

    Takeda

    Myeloma, Multiple

    phase 2 small molecule active

    1 trial

  35. Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, IMBRUVICA 140 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 15 mg hard capsules, JNJ-54179060, Lenalidomide Accord 2.5 mg hard capsules, Ruxi

    Janssen-Cilag International N.V.

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  36. Lenalidomide [Leavdo®]

    Hospital Authority, Hong Kong

    Antibiotics-unresponsive MALT Lymphoma

    phase 2 small molecule active

    1 trial

  37. Lenalidomide and Gemcitabine (Dose level 11)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T-cell Lymphomas (PTCL)

    phase 2 small molecule terminated

    1 trial

  38. Lenalidomide combined with G-CHOP (LO CHOP)

    The First People's Hospital of Lianyungang

    DLBCL - Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  39. Lenvatinib

    United Therapeutics Europe Ltd

    Columnar Cell Variant Thyroid Gland Papillary Carcinoma

    phase 2 small molecule completed

    1 trial

  40. Lenvatinib

    The First People's Hospital of Lianyungang

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  41. Lenvatinib

    Eisai Co.,

    Osteosarcoma

    phase 2 small molecule completed

    1 trial

  42. Lenvatinib, Belzutifan, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    Patients with localized renal cell carcinoma

    phase 2 small molecule active

    1 trial

  43. Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib

    The George Institute

    Resectable mucosal melanomas

    phase 2 small molecule active

    1 trial

  44. Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, MK-1308A

    Merck Sharp and Dohme

    Advanced melanoma with brain metastases, PD-1 refractory or PD-1 naive

    phase 2 small molecule active

    1 trial

  45. Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion., Lenvatinib

    Fondazione Telethon ETS

    vulvar cancer

    phase 2 small molecule active

    1 trial

  46. Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments.

    phase 2 small molecule active

    1 trial

  47. Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830, ETOPOSIDE, Lenvatinib, CISPLATIN, boserolimab, CARBOPLATIN

    Merck Sharp and Dohme

    First-line treatment of participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  48. Lenvatinib, Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarcoma (RMS), Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (pPNET), or other solid tumor types (except osteosarcoma)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.